Water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases
View Patent ↗The invention relates to novel, water-soluble porphyrin platinum compounds of the tetraarylporphyrin platinum derivatives type or of the hematoporphyrin platinum derivatives type with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases. In particular, the compounds are suitable for photodynamic anti-tumor therapy.
1. A porphyrin platinum derivative of the (a) tetraarylporphyrin platinum derivative type
according to formula I
or according to formula II
or
(b) hematoporphyrin platinum derivative type
according to formula IV
2. A compound according to claim 1 , being in the form of a racemate, enantiomer or diastereoisomer thereof.
3. A method for photodynamic treatment of a cancer, comprising administering a compound according to claim 1 to a patient in need thereof.
4. A method for photodynamic treatment of a tumor, comprising administering a compound according to claim 1 to a patient in need thereof.
5. The method of claim 4 , further comprising irradiating with electromagnetic radiation having a wavelength of 600 to 730 nm.
6. A composition comprising one or more compounds according to claim 1 and a physiologically tolerable carrier, diluent or auxiliary.
7. A method for photodynamic treatment of a cancer, comprising administering a compound according to claim 2 to a patient in need thereof.
8. A method for photodynamic treatment of a tumor, comprising administering a compound according to claim 2 to a patient in need thereof.
9. The method of claim 8 , further comprising irradiating with electromagnetic radiation having a wavelength of 600 to 730 nm.
10. A composition comprising one or more compounds according to claim 2 and a physiologically tolerable carrier, diluent or auxiliary.
11. The compound according to claim 1 , selected from the group consisting of:
Diammine[2-(4-[10,15,20-tris[4-(1,4,7-trioxaocryl)phenyl]porphyrin-5-yl } phenoxy)malonato]platinum (II);
(±)-trans-1,2-Diaminocyclohexane[2-(4{ 10,15,20-tris[4-(1,4,7,10 -tetraoxaundecyl)phenyl]porphyrin-5-yl} phenoxy) malonato[platinum(II);
(±)-trans-1,2-Diaminocyclohexane{7,12-bis[1-( 1,4,7,10,13,16 -hexaoxaheptadecyl) ethyl]-3,8,13,17-tetramethylporphyrin-2,18-dipropionato} platinum(II); and
2,2′ -Bipyridyl (7,12-bis[1-(1 ,4,7-trioxaocryl)ethyl]3,8,13,17-tetramethylporphyrin-2,18 -dipropionato } platinum(II).
12. A method for photodynamic treatment of a cancer, comprising administering a compound according to claim 11 to a patient in need thereof.
13. A method for photodynamic treatment of a tumor, comprising administering a compound according to claim 11 to a patient in need thereof.
14. The method of claim 13 , further comprising irradiating with electromagnetic radiation having a wavelength of 600 to 730 nm.
15. A composition comprising one or more compounds according to claim 11 and a physiologically tolerable carrier, diluent or auxiliary.
16. A porphyrin platinum derivative of the hematoporphyrin platinum derivative type according to formula III
17. The compound of claim 16 , wherein n=1-8.
18. The compound of claim 16 , which is diammine{7,12-bis[1-(1,4,7-trioxaoctyl)ethyl]-3,8,13,17-tetramethylporphyrin-2,18-dipropionato } platinum(II).
19. A method for phorodynamic treatment of a cancer, comprising administering a compound according to claim 16 in a patient in need thereof.
20. A method for photodynamic treatment of a tumor, comprising administering a compound according to claim 16 to a patient in need thereof.
21. The method of claim 20 , further comprising irradiating with electromagnetic radiation having a wavelength of 600 to 730 nm.
22. A composition comprising one or more compounds according to claim 16 and a physiologically tolerable carrier, diluent or auxiliary.